ClinicalTrials.gg
Not yet recruitingNCT07946484Updated Nov 18, 2026

Acupuncture for Depression: Sigma-1 Receptor-Related Brain Network Modulation

An interventional study of Acupuncture and Pivot Acupuncture in Depression Disorder, sponsored by Shenzhen Hospital of Guangzhou University of Chinese Medicine. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shenzhen Hospital of Guangzhou University of Chinese Medicine · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will compare two types of acupuncture for adults with mild to moderate depression. One group will receive acupuncture. The other group will receive pivot acupuncture, a technique that uses needles at points on the head and neck. Participants with depression will be assigned to one of the two groups by chance. Both groups will attend three sessions a week for six weeks.

The researchers will compare how many people in each group have a substantial improvement in their depression symptoms by the end of treatment. They will also use brain scans and blood tests to examine whether symptom improvement is related to changes in how different parts of the brain work together and to changes in blood levels of a protein called the sigma-1 receptor.

Read the detailed description

In this parallel-group randomized trial, 72 adults with a mild to moderate depressive episode will be assigned in a 1:1 ratio to acupuncture or pivot acupuncture. The allocation sequence will be generated using SAS and concealed in sequentially numbered, opaque, sealed envelopes until treatment assignment.

Structural brain MRI, resting-state functional MRI, and peripheral blood sampling will be performed at baseline and at the end of the six-week treatment period. The personalized brain functional sectors (pBFS) method will be used to define 92 functional brain regions for each participant and estimate pairwise functional connectivity. The investigators will examine associations among changes in connectivity, peripheral sigma-1 receptor levels, and depressive symptoms. They will also explore whether changes in connectivity can estimate the magnitude of symptom improvement and compare models based on individualized and group-level brain maps.

02

Conditions studied

  • Depression Disorder

Browse trials for

Keywords

  • depression
  • sigma-1
  • resting-state functional MRI
  • acupuncture
03

In context

Depression

8,602 studies on the registry are indexed under Depression; 1,735 are open to participants now.

This study's planned enrollment of 72 is below the median of 81 across 7,083 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

This is the only study on the registry with Shenzhen Hospital of Guangzhou University of Chinese Medicine as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 60 years, inclusive.
  • Right-handed.
  • Diagnosed with a depressive episode according to ICD-10 code F32 and meeting criteria for a depressive episode.
  • Mild to moderate depressive symptoms, defined as a baseline score of at least 8 and less than 24 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • No use of immunomodulators, antidepressants, or other medications that affect mood in the month before enrollment.
  • Willing and able to follow study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Another psychiatric disorder, such as bipolar disorder or schizophrenia.
  • disease or acute infection.
  • Intellectual disability (IQ below 70) or autism spectrum disorder.
  • History of epilepsy or a brain lesion.
  • History of drug dependence.
  • A to acupuncture, electroacupuncture, or MRI, such as an infectious condition that precludes needling, a history of fainting with needling, claustrophobia, or an MRI-incompatible intracranial implant.
  • Suicide risk identified at screening.
  • Current participation in another clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Acupuncture

    Participants will receive acupuncture three times a week for six weeks, for a total of 18 sessions. Each session will last 30 minutes.

    Procedure: Acupuncture

  • Active comparator
    Pivot Acupuncture

    Participants will receive pivot acupuncture three times a week for six weeks, for a total of 18 sessions. Needles will be retained for 20 minutes at each session.

    Procedure: Pivot Acupuncture

Interventions

  • ProcedureAcupuncture

    The primary points are Baihui (GV20) and Yintang. Baihui is needled transversely from anterior to posterior to a depth of 0.5-0.8 cun. Yintang is needled slowly in a superior direction to a depth of 0.5-0.8 cun and gently rotated to de qi. Additional points are Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zusanli (ST36), and Taichong (LR3). Sterile acupuncture needles measuring 0.30 × 25 mm or 0.30 × 40 mm are used. Qualified practitioners with at least five years of clinical experience administer treatment.

  • ProcedurePivot Acupuncture

    Needles are placed at Fengfu (GV16), Naohu (GV17), and bilateral Fengchi (GB20), Tianzhu (BL10), Wangu (GB12), Yifeng (TE17), Tianyou (TE16), and Anmian. With participants supine, the skin is disinfected with 75% alcohol. Sterile, single-use Huanqiu needles (Suzhou Huanqiu Acupuncture Medical Appliance Co., Ltd., China), 0.30 × 25 mm or 0.30 × 40 mm, are inserted rapidly. Fengchi is needled obliquely toward the tip of the nose to a depth of 10-23 mm. Fengfu is needled straight toward the mandible to a depth of 10-23 mm. Naohu is needled obliquely downward to a depth of 23 mm. Tianzhu, Wangu, Yifeng, Tianyou, and Anmian are needled perpendicularly to a depth of 30 mm. Needles are manipulated by lifting, thrusting, and rotating, then retained for 20 minutes. Treatment is administered without electrical stimulation.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Clinical Response on the HAMD-17

    Clinical response is defined as a reduction of at least 50% from baseline in the total score on the 17-item Hamilton Depression Rating Scale (HAMD-17). The HAMD-17 is a clinician-rated measure of depressive symptom severity. Total scores range from 0 to 52, with higher scores indicating more severe symptoms.

    Time frame: Baseline and Week 6 (end of treatment).

Secondary outcomes

  1. Percentage of Participants in Remission on the HAMD-17

    Remission is defined as a total score below 8 on the 17-item Hamilton Depression Rating Scale (HAMD-17).

    Time frame: Week 6 (end of treatment).

  2. Change From Baseline in HAMD-17 Total Score

    The Week 6 total score minus the baseline total score on the 17-item Hamilton Depression Rating Scale. Total scores range from 0 to 52, with higher scores indicating more severe symptoms. A negative change indicates improvement.

    Time frame: Baseline and Week 6 (end of treatment).

  3. Change From Baseline in SF-12 Summary Score

    The 12-Item Short Form Health Survey (SF-12) is a self-reported measure of health status. Higher scores indicate better physical health. Change is calculated as the Week 6 score minus the baseline score.

    Time frame: Baseline and Week 6 (end of treatment).

  4. Change From Baseline in BC-CCI-E Cognitive Complaints Score

    The British Columbia Cognitive Complaints Inventory-Expanded (BC-CCI-E) is a self-report measure of perceived cognitive difficulties. Higher cognitive complaints scores indicate more severe difficulties. Change is calculated as the Week 6 score minus the baseline score.

    Time frame: Baseline and Week 6 (end of treatment).

  5. Suicide risk monitoring

    Suicide risk will be assessed at baseline and weekly during the six-week treatment period using the Columbia-Suicide Severity Rating Scale (C-SSRS).

    Time frame: From enrollment through Week 10

Other outcomes

  1. Percentage of Participants With at Least One Adverse Event

    Adverse events will be recorded from enrollment through the final follow-up visit. The number and percentage of randomized participants with at least one adverse event will be summarized by treatment group.

    Time frame: From enrollment through Week 10

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 3,483 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 3,581 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946484
Lead sponsor
Shenzhen Hospital of Guangzhou University of Chinese Medicine
Responsible party
Xinjing Yang (Doctor, Shenzhen Hospital of Guangzhou University of Chinese Medicine) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Xinjing Yang, Doctor
Contact
yangxinjing120@163.com
86+18813989594

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion